PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53

Cancer Genetics and Cytogenetics

Volumn 182, Issue 1, 2008, Pages 33-39

  Pärssinen, Jenita ^a   Alarmo, Emma Leena ^a   Karhu, Ritva ^a   Kallioniemi, Anne ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P53; RNA;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL DEATH; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE; GENE ACTIVATION; GENE AMPLIFICATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE; PHENOTYPE; PPM1D GENE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENES, P53; HUMANS; PHOSPHOPROTEIN PHOSPHATASES; RNA INTERFERENCE;

EID: 40049086948     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.12.013     Document Type: Article

References (25)

1. Fiscella M., Zhang H., Fan S., Sakaguchi K., Shen S., Mercer W.E., Vande Woude G.F., O'Connor P.M., and AppellaWip1 E. a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 94 (1997) 6048-6053
2. Choi J., Appella E., and Donehower L.A. The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics 64 (2000) 298-306
3. Takekawa M., Adachi M., Nakahata A., Nakayama I., Itoh F., Tsukuda H., Taya Y., and Imai K. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19 (2000) 6517-6526
4. arf pathway. Nat Genet 36 (2004) 343-350
5. Lu X., Bocangel D., Nannenga B., Yamaguchi H., Appella E., and Donehower L.A. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell 15 (2004) 621-634
6. Lu X., Nannenga B., and Donehower L.A. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev 19 (2005) 1162-1174
7. Shreeram S., Demidov O.N., Hee W.K., Yamaguchi H., Onishi N., Kek C., Timofeev O.N., Dudgeon C., Fornace A.J., Anderson C.W., Minami Y., Appella E., and Bulavin D.V. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell 23 (2006) 757-764
8. Shreeram S., Hee W.K., Demidov O.N., Kek C., Yamaguchi H., Fornace Jr. A.J., Anderson C.W., Appella E., and Bulavin D.V. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med 203 (2006) 2793-2799
9. Fujimoto H., Onishi N., Kato N., Takekawa M., Xu X.Z., Kosugi A., Kondo T., Imamura M., Oishi I., Yoda A., and Minami Y. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ 13 (2006) 1170-1180
10. Oliva-Trastoy M., Berthonaud V., Chevalier A., Ducrot C., Marsolier-Kergoat M.C., Mann C., and Leteurtre F. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 26 (2006) 1449-1458
11. Bulavin D.V., Demidov O.N., Saito S., Kauraniemi P., Phillips C., Amundson S.A., Ambrosino C., Sauter G., Nebreda A.R., Anderson C.W., Kallioniemi A., Fornace Jr. A.J., and Appella E. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 31 (2002) 210-215
12. Li J., Yang Y., Peng Y., Austin R.J., van Eyndhoven W.G., Nguyen K.C., Gabriele T., McCurrach M.E., Marks J.R., Hoey T., Lowe S.W., and Powers S. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 31 (2002) 133-134
13. Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A., Sugimoto T., and Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 63 (2003) 1876-1883
14. Hirasawa A., Saito-Ohara F., Inoue J., Aoki D., Susumu N., Yokoyama T., Nozawa S., Inazawa J., and Imoto I. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 9 (2003) 1995-2004
15. Mendrzyk F., Radlwimmer B., Joos S., Kokocinski F., Benner A., Stange D.E., Neben K., Fiegler H., Carter N.P., Reifenberger G., Korshunov A., and Lichter P. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23 (2005) 8853-8862
16. Rauta J., Alarmo E.L., Kauraniemi P., Karhu R., Kuukasjarvi T., and Kallioniemi A. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 95 (2006) 257-263
17. Demidov O.N., Kek C., Shreeram S., Timofeev O., Fornace A.J., Appella E., and Bulavin D.V. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 26 (2007) 2502-2506
18. Harrison M., Li J., Degenhardt Y., and Hoye T. Powers Scott. Wip1-deficient mice are resistant to common cancer genes. Trends Mol Med 10 (2004) 359-361
19. Bärlund M., Nupponen N.N., Karhu R., Tanner M.M., Paavola P., Kallioniemi O.P., and Kallioniemi A. Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17. Cytogenet Cell Genet 82 (1998) 189-191
20. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
21. Choi J., Nannenga B., Demidov O.N., Bulavin D.V., Cooney A., Brayton C., Zhang Y., Mbawuike I.N., Bradley A., Appella E., and Donehower L.A. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol 22 (2002) 1094-1105
22. Schito M.L., Demidov O.N., Saito S., Ashwell J.D., and Appella E. Wip1 phosphatase-deficient mice exhibit defective T cell maturation due to sustained p53 activation. J Immunol 176 (2006) 4818-4825
23. Runnebaum I.B., Nagarajan M., Bowman M., Soto D., and Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A 88 (1991) 10657-10661
24. Hershko T., Korotayev K., Polager S., and Ginsberg D. E2F1 modulates p38 MAPK phosphorylation via transcriptional regulation of ASK1 and Wip1. J Biol Chem 281 (2006) 31309-31316
25. Belova G.I., Demidov O.N., Fornace Jr. A.J., and Bulavin D.V. Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis. Cancer Biol Ther 4 (2005) 1154-1158